Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

3.33 (USD) • At close December 27, 2024
Bedrijfsnaam Atea Pharmaceuticals, Inc.
Symbool AVIR
Munteenheid USD
Prijs 3.33
Beurswaarde 281,262,123
Dividendpercentage 0%
52-weken bereik 2.75 - 4.6
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jean-Pierre Sommadossi Ph.D.
Website https://ateapharma.com

An error occurred while fetching data.

Over Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752,

Vergelijkbare Aandelen

Atai Life Sciences N.V. logo

Atai Life Sciences N.V.

ATAI

1.28 USD

InnovAge Holding Corp. logo

InnovAge Holding Corp.

INNV

3.92 USD

Aurora Cannabis Inc. logo

Aurora Cannabis Inc.

ACB

4.3 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

31.75 USD

iTeos Therapeutics, Inc. logo

iTeos Therapeutics, Inc.

ITOS

7.32 USD

ZimVie Inc. logo

ZimVie Inc.

ZIMV

14.04 USD

Avidity Biosciences, Inc. logo

Avidity Biosciences, Inc.

RNA

30.11 USD

Nkarta, Inc. logo

Nkarta, Inc.

NKTX

2.41 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)